AI Article Synopsis

  • Two groups of 15 laboratory dogs were vaccinated with different rabies vaccines (RABISIN for group A and NOBIVAC for group B) and monitored for antibody levels over 4 months.
  • Group A dogs had significantly higher rabies antibody titers compared to group B at multiple time points after vaccination.
  • The study emphasizes the importance of choosing the right vaccine and timing blood tests for effective rabies immunity, with RABISIN showing better and longer-lasting results.

Article Abstract

Thirty laboratory dogs were randomly assigned to two groups (A and B) of 15 dogs and subcutaneously vaccinated with a single dose of one of two commercially available monovalent inactivated rabies vaccines: RABISIN (Merial, France) (group A) and NOBIVAC Rabies (Intervet International) (group B). Rabies antibodies were measured over a period of 4 months using the fluorescent antibody virus neutralization (FAVN) test. The two vaccines performed differently in terms of magnitude and persistence of rabies antibodies titers in dogs. Two weeks after vaccination, average rabies antibody titers peaked at 2.53 IU/mL (range, 0.17-13.77 IU/mL) and 1.26 IU/mL (range, 0.50-4.56 IU/mL) in groups A and B dogs, respectively. The average FAVN antibody titres against rabies on D28, D56, D84, D112 and D120 were significantly higher in group A than in group B. Although all dogs from group B serologically responded to vaccination, the proportion of dogs with antibody titres >or=0.5 IU/mL dropped significantly after D28 and was statistically significantly lower on D56, D84 and D112 compared to group A dogs. In conclusion, in the context of international trade, the choice of the vaccine and the timing of blood tests are critical factors in achieving successful serological test results after rabies vaccination. RABISIN induces high and sustained antibody titres against rabies, increasing the flexibility for the time of blood sampling after primo-vaccination.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.vetmic.2008.06.024DOI Listing

Publication Analysis

Top Keywords

antibody titres
12
rabies
9
inactivated rabies
8
rabies vaccines
8
groups dogs
8
rabies antibodies
8
iu/ml range
8
titres rabies
8
d56 d84
8
d84 d112
8

Similar Publications

Helicobacter pylori-Related Chronic Gastritis as a Risk Factor for Lower Bone Mineral Density.

Calcif Tissue Int

January 2025

Department of Gastroenterology, School of Medicine, Wakayama Medical University, 811-1 Kimiidera, Wakayama, Wakayama, 641-0012, Japan.

We evaluated the role of Helicobacter pylori (H. pylori)-related chronic gastritis in the development of osteoporosis in a population-based study. A total of 1690 subjects in the cohort of the Research on Osteoarthritis/ osteoporosis Against Disability (ROAD) were investigated, and the association between gastritis and osteoporosis was evaluated by the presence of serologically assessed H.

View Article and Find Full Text PDF

Elimination of oral foci of infection might lead to clinical improvement of Graves' orbitopathy.

Graefes Arch Clin Exp Ophthalmol

January 2025

Department of Endocrinology, Metabolism and Internal Medicine, Poznan University of Medical Sciences, Przybyszewskiego 49, 60-355, Poznan, Poland.

Purpose: Graves' disease (GD) and Graves' orbitopathy (GO) are multifactorial disorders with links to the gut microbiome and autoimmunity. It is observed that patients with GD exhibit altered gut microbiome diversity. However, little is known about the role of oral microbiota in GD and GO.

View Article and Find Full Text PDF

Evaluation of a nanostructured CpG-ODN/ascorbyl palmitate as a safe and effective adjuvant for anticrotalic PLA2 serum.

Trans R Soc Trop Med Hyg

January 2025

Conse jo Nacional de Investigaciones Científicas y Técnicas (CONICET), Instituto de Química Básica y Aplicada del Nordeste Argentino (IQUIBA-NEA), CP3400 Corrientes, Argentina.

Background: The WHO states that antivenom is the only safe and effective treatment to neutralize snake venom. Snakebite antivenom typically involves horse hyperimmunization with crude venom and Freund's adjuvant.

Methods: In the current work, we analyzed the ascorbyl palmitate liquid crystal structure with snake protein or PLA2, the carrier charge capacity, and we evaluated the immune response induced by the enzyme P9a(Cdt-PLA2) formulated in a nanostructure using CpG-ODN, determining the titer of IgG antibodies.

View Article and Find Full Text PDF

Background: The emergence of new SARS-CoV-2 variants poses a new challenge for the treatment of immunocompromised patients against COVID-19. In this context, high titer COVID-19 Convalescent Plasma (CCP) is one of the few available therapeutics for these patients. We have revisited the selection of CCP samples and its efficacy against Omicron XBB.

View Article and Find Full Text PDF

Background: Biosimilar natalizumab (biosim-NTZ) is the first biosimilar monoclonal antibody of reference natalizumab (ref-NTZ) for treatment of relapsing forms of multiple sclerosis (MS). Within the totality of evidence for demonstration of biosimilarity, immunogenicity assessments were performed in healthy subjects and patients with relapsing-remitting MS (RRMS) to confirm a matching immunogenicity profile between biosim-NTZ and ref-NTZ.

Methods: Immunogenicity of biosim-NTZ versus ref-NTZ was evaluated in two pivotal clinical studies.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!